Latest healthtech and biotech deals
The largest from last week:
๐บ๐ธ Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, announced a Series B funding of $225M.
๐บ๐ธ CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, closed a $100M Series B round to advance the companyโs lead regRNA programs and accelerate the expansion of the companyโs regRNA Actuating Platform.
๐บ๐ธ BigHat Biosciences, a biotechnology company developing antibody therapies for patients using machine learning and synthetic biology, raised a $75M Series B funding round.
๐ฎ๐น MMI, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75M in Series B financing.
Other notable deals from around the globe:
๐ฎ๐ฑ ForSight Robotics finished a $55M Series A round for its surgical platform for fully robotic cataract surgery. The platform, named ORYOM, will increase accessibility to ophthalmic surgery procedures worldwide.
๐บ๐ธ Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, closed its $48M Series A financing round.
๐บ๐ธ Centivo, an innovative provider of health plans for self-insured employers built to address health care affordability for employees and their families, received a $30M investment from Morgan Health: the JPMorgan Chase & Co. (NYSE: JPM) business unit focused on improving the quality, equity and affordability of employer-sponsored health care.
Read up on all the latest health deals in Dealroom.co